Envista Holdings (DE:0HV)
NYSE:0HV
0HV Stock Chart & Stats
€22.40
€0.00(0.00%)
Market closed
€22.40
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€16.20 - €25.80
Previous CloseN/A
Volume246.00
Average Volume (3M)0.00
Market Cap
€3.85B
Enterprise Value€4.55B
Total Cash (Recent Filing)€1.08B
Total Debt (Recent Filing)€1.59B
Price to Earnings (P/E)64.2
Beta0.55
Next Earnings
Aug 05, 2026EPS Estimate
0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.42
Shares Outstanding162,727,920
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.74
Price to Book (P/B)1.17
Price to Sales (P/S)1.34
P/FCF Ratio15.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€25.63Price Target Upside14.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)1.24
Revenue Forecast (FY)€2.48B
Bulls Say, Bears Say
Bulls Say
Free Cash Flow GenerationEnvista's trailing‑twelve‑month operating cash flow ($272.1M) and free cash flow ($220.2M) show durable cash conversion. Reliable FCF supports reinvestment in manufacturing and digital platforms, accretive tuck‑ins, and continued share repurchases, providing financial flexibility through cycles.
High And Improving Gross MarginsSustained ~55% gross margins and recent 100bp improvement reflect durable product mix skewed to consumables and proprietary implants/technology. Higher gross margins provide structural cushioning against cost inflation and support sustained EBITDA expansion and funding for R&D and commercialization.
Product Innovation & Strategic M&ANew product introductions and targeted tuck‑ins (e.g., Nobel S Series, Spark, DEXIS enhancements, Versah) strengthen competitive differentiation and drive conversion of competitors' customers. Innovation plus bolt‑on M&A increases recurring consumables attach rates and supports medium‑term share gains.
Bears Say
Thin Net Margins & Earnings VolatilityDespite recent profitability, net margins are narrow (~2.4%) and prior multi‑year volatility (losses in 2023–24) shows recovery risk. Thin bottom‑line profitability limits capacity to self‑fund large investments and makes results sensitive to volume, pricing, or cost shocks over the medium term.
Material Debt Load Limits FlexibilityLeverage around 0.5x and total debt near $1.6B are manageable but meaningful. If the earnings recovery stalls, debt servicing and covenant cushion could constrain larger strategic investments or accelerate deleveraging, reducing optionality for bigger transformative M&A or capital spending.
China VBP & Channel Destocking RiskChannel destocking ahead of volume‑based procurement (VBP) in China creates structural timing risk and reimbursement uncertainty for implants. VBP transitions can compress near‑term orders and margins and introduce elongated recovery periods even if long‑term adoption stabilizes.
Envista Holdings News
0HV FAQ
What was Envista Holdings’s price range in the past 12 months?
Envista Holdings lowest stock price was €16.20 and its highest was €25.80 in the past 12 months.
What is Envista Holdings’s market cap?
Envista Holdings’s market cap is €3.85B.
When is Envista Holdings’s upcoming earnings report date?
Envista Holdings’s upcoming earnings report date is Aug 05, 2026 which is in 38 days.
How were Envista Holdings’s earnings last quarter?
Envista Holdings released its earnings results on May 06, 2026. The company reported €0.316 earnings per share for the quarter, beating the consensus estimate of €0.274 by €0.042.
Is Envista Holdings overvalued?
According to Wall Street analysts Envista Holdings’s price is currently Undervalued.
Does Envista Holdings pay dividends?
Envista Holdings does not currently pay dividends.
What is Envista Holdings’s EPS estimate?
Envista Holdings’s EPS estimate is 0.29.
How many shares outstanding does Envista Holdings have?
Envista Holdings has 162,727,920 shares outstanding.
What happened to Envista Holdings’s price movement after its last earnings report?
Envista Holdings reported an EPS of €0.316 in its last earnings report, beating expectations of €0.274. Following the earnings report the stock price went up 11.818%.
Which hedge fund is a major shareholder of Envista Holdings?
Currently, no hedge funds are holding shares in DE:0HV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Envista Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€25.63 (14.42% Upside)
€25.63 (14.42% Upside)
Blogger Sentiment
Bullish
DE:0HV Sentiment 70%
Sector Average ―
Sector Average ―
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.20%
12-Months-Change
Fundamentals
Return on Equity
2.18%
Trailing 12-Months
Asset Growth
2.04%
Trailing 12-Months
Company Description
Envista Holdings
Envista Holdings Corporation is an enterprise dedicated to the development and distribution of a comprehensive range of dental solutions. These offerings are crucial for the identification, therapeutic intervention, and preventative care of diverse oral health issues, specifically addressing the teeth, gingiva (gums), and their supporting bone structures. The company's principal location is in Brea, California, and it maintains a workforce comprising 12,800 full-time personnel. The firm organizes its business activities into two main divisions: "Specialty Products & Technologies" and "Equipment & Consumables." The Specialty Products & Technologies division concentrates on the creation, fabrication, and promotion of sophisticated dental implant systems, advanced prosthetic devices, and their associated digital treatment software and technological advancements. This segment also provides orthodontic remedies, including bracket systems, clear aligners, and various items for dental laboratories. Conversely, the Equipment & Consumables division is responsible for conceptualizing, producing, and bringing to market a wide array of dental apparatus and vital supplies intended for professional dental clinics. This extensive catalog includes digital imaging instruments, specialized software, and visual or magnification systems; patient treatment units and other essential fixtures for dental practices; complete endodontic kits along with their complementary consumable items; materials and tools for restorative dentistry; rotary cutting tools (burs); impression-making compounds; adhesive agents and dental cements; and products designed for infection control.
0HV Company Deck
0HV Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed broad-based operational and commercial progress: healthy top-line growth (9.5% core, ~4% normalized), margin expansion (gross margin +100 bps, EBITDA margin +120 bps), strong EPS improvement (+50%), meaningful new-product momentum, accretive tuck-in M&A, and continued capital returns (incremental $300M buyback). Key near-term headwinds include China implant destocking ahead of VBP, elevated tariff costs (~$11M), Q1 negative FCF due to CapEx, and geopolitical-driven inflation/freight risks — all of which management has identified and presented mitigation plans for. Overall, the positives on growth, margins, product launches and capital allocation materially outweigh the manageable near-term challenges.View all DE:0HV earnings summaries0HV Revenue Breakdown
63.99% Specialty Products & Technologies
36.01% Equipment & Consumables
0HV Stock 12 Month Forecast
Average Price Target
€25.63
▲(14.42% Upside)
Technical Analysis
DENTSPLY SIRONA
―
Disc Medicine
―
Clover Health Investments
―
AbCellera Biologics
―
Bausch + Lomb Corporation
―
Options Prices
Currently, No data available
---